Cancer Clinical Trials & Research

About cCARE’s cancer research

cCARE is proud to offer numerous institutional-grade clinical trials for cancer patients. Clinical trials assess new drug or treatment effectiveness and provide cancer patients with the newest – and possibly most effective – forms of treatment.

Cancer clinical trials are divided into three different phases. Phase I trials assess the safety of a drug or treatment; phase II trials quantify how effective the treatment is while phase III compares the trial to the best existing cancer treatment.

The decision to participate in a cancer clinical trial should be made early in the diagnosis stage because once treatment begins, patients may not be eligible to participate in certain clinical trials. Benefits of participating in cancer clinical trials include access to the newest treatment and medicine designed to fight your particular type of cancer as well as being monitored closely throughout the treatment process.

Although clinical trials provide many benefits, patients must consider the risks as well. Participants may experience unforeseen side effects, the treatment may just not work as well as previous methods and health insurance coverage may not extend to participating in a trial. Speak with your oncologist about whether or not a clinical trial is right for your specific case.

Open cancer clinical trials at cCARE

Below is a list of cancer clinical trials currently open at cCARE. If you have any questions please call us at (760) 452-3909 or email Beth Kimball, RN OCN, Clinical Research Manager, at [email protected].

San Diego cancer clinical trials – (jump to Fresno clinical trials)

Advanced Solid Malignancies

Title: A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies

This is a Phase I, open-label, multicenter study of continuous oral dosing of AZD4635 administered as a single agent and then in combination with a PD-L1 antibody, durvalumab. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients. The primary objective of the study is to determine the maximum tolerated dose of AZD4635 in combination with durvalumab.

Learn More About This Cancer Study


Advanced Solid Tumors Clinical Trial

Title: Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule

This is a two stage, open label, randomized-sequence, single-crossover Phase 1 study to evaluate the relative bioavailability (BA) of niraparib administered as a tablet formulation compared to the reference capsule formulation currently marketed in the United States. Specifically, a 300 mg niraparib tablet will be compared to 3 niraparib capsules (3 × 100 mg). The Extension Phase of this study is to enable patients enrolled in the study to continue to receive treatment with niraparib tablets if they are tolerating it and, in the Investigator’s opinion, may receive benefit.

Learn More About This Cancer Study


Advanced Solid Tumors Clinical Trial 

Title: A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors

An open-label, dose escalation clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors.

Learn More About This Cancer Study


Advanced Solid Tumors Clinical Trial

Title: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Learn More About This Cancer Study


Advanced Solid Tumors Clinical Trial 

Title: Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)

This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive MK-4280 as monotherapy or MK-4280 in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RPTD) for MK-4280 in combination with pembrolizumab in participants with advanced solid tumors.

Learn More About This Cancer Study


Advanced or Metastatic Solid Tumors Clinical Trial

Title: Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 or With TSR-042 and Bevacizumab

Part A: To test the safety and tolerability of combination therapy with Niraparib and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part B: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel and TSR-042 and to establish a safe dose that will be used in a Phase 2 study.

Part C: To test the safety and tolerability of combination therapy with Niraparib, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Part D: To test the safety and tolerability of combination therapy with Carboplatin-Paclitaxel, TSR-042 and Bevacizumab and to establish a safe dose that will be used in a Phase 2 study.

Learn More About This Cancer Study


Advanced or Metastatic Solid Tumors Clinical Trial

Title: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody TSR-042 in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Learn More About This Cancer Study


Advanced/Metastatic Microsatellite Stable Colorectal Cancer Clinical Trial

Title: Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).

Learn More About This Cancer Study


Endocrine Therapy for Breast Cancer Clinical Trial

Title: Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Learn More About This Cancer Study


HER2 Negative, HR Positive, MBC Clinical Trial

Title: Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA) (CONTESSA)

The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting.

Approximately 600 eligible patients will be randomly assigned in a 1:1 ratio to either Arm A (tesetaxel plus a reduced dose of capecitabine) or Arm B (approved dose of capecitabine alone).

Learn More About This Cancer Study


M9241 (NHS-IL12)

Title: A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (COMBO)

The study consists of 2 parts: Dose Escalation phase (Part A) and Expansion phase (Part B). The dose escalation phase will evaluate the safety, tolerability, and PK of avelumab in combination with NHS-IL12 in subjects with locally advanced, unresectable, or metastatic solid tumors. Expansion phase will assess the safety and clinical activity of the combination regimen in selected tumor types. In Expansion phase subjects who have completed the combination treatment of avelumab at a given dose level of NHS-IL12, a safety review will be performed by the Safety monitoring committee in order to make a decision on the next dose level. Successive cohorts of 3 to 6 subjects will be treated with escalating doses of NHS-IL12 with avelumab intravenous (IV).

Learn More About This Cancer Study


Locally Advanced or Metastatic RAS-mutant Solid Tumors Clinical Trial

Title: A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors

This Phase 1b/2 study will examine the effects of the study drugs, avelumab and binimetinib given together (doublet) and in combination with talazoparib (triplet), in patients with locally advanced or metastatic RAS-mutant solid tumors. The Phase 1b part of the study will assess if the different study drugs can be given together safely and which doses to use for further research. Phase 2 will test if the study treatments have an effect on tumor size and growth, and gather more information about potential side effects.

Learn More About This Cancer Study


Metastatic or Locally Advanced Solid Tumors Clinical Trial

Title: MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors

The main purpose of this Phase I study is to test MSB0011359C (M7824) at different dose levels to see if it is safe and well tolerated when given once every 2 weeks. Phase I means the study drug has not previously been given to humans or has only been given to a limited number of people, although it has been extensively studied in animals. Based on this information, it is hoped to find out which dose could be best for the treatment of patients. There are two parts of this research study: a dose-escalation part and an expansion part. Dose escalation means that the first people taking part in the study will receive low doses of the study drug, and as more people take part, the additional participants will receive a higher dose. This is done to find the safest dose for the study drug. Expansion means that after the dose-escalation part of the study has looked at the safety and effectiveness of different doses, many more people will be invited to take part in the study and will receive the study drug at the safest dose. Additional purposes of the study are to find out whether the study drug has anti-cancer effects and how the study drug is processed by the body.

Learn More About This Cancer Study

 


Multiple Myeloma Clinical Trial 

Title: Combination Study for High Risk Multiple Myeloma Patients

Despite the recent introduction of novel anti-multiple myeloma agents, high risk multiple myeloma remains with poor prognosis and a therapeutic challenge. In this study, the investigators propose to evaluate efficacy and safety of elotuzumab in combination with pomalidomide, dexamethasone and carfilzomib for high-risk relapsed/refractory multiple myeloma patients.

Learn More About This Cancer Study


Multiple Myeloma Clinical Trial

Title: Pomalidomide for Lenalidomide for Failures

The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of pomalidomide given as part of a combination therapy that include more than just steroids to treat subjects with relapsed (subjects whose disease came back) or refractory (subjects whose disease did not respond to past treatment) multiple myeloma (MM).

Learn More About This Cancer Study


Newly Diagnosed Glioblastoma Multiforme Clinical Trial

Title: A Feasibility Study of the Nativis Voyager® System in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 32 subjects and will be combined with standard of care radiotherapy and temozolomide.

Learn More About This Cancer Study


Non Hodgkin Lymphoma Clinical Trial

Title: Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab (JASMINE)

This trial is designed to determine what effects the human body has on the investigational medicine, ABP 798, and what effects the body has on the investigational medicine after you have been given it, and if this is comparable to what is seen for the licensed medicine, rituximab, in patients with CD 20 positive B-cell non Hodgkin lymphoma. This study will assess if the investigational medicine is safe and effective in treating CD 20 positive B-cell non Hodgkin lymphoma.

Learn More About This Cancer Study


Recurrent Glioblastoma Multiforme Clinical Trial

Title: A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with first or second recurrence of GBM who have either failed standard of care or are intolerant to therapy. The study will enroll and treat up to 32 subjects with Voyager plus lomustine with or without bevacizumab. Safety and clinical utility will be evaluated.

Learn More About This Cancer Study


Relapsed/Refractory Multiple Myeloma Clinical Trial

Title: A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

Learn More About This Cancer Study


Solid Tumors, Melanoma, Prostate, Renal Cell & Hepatocellular Carcinoma Clinical Trial

Title: Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors

The goal of this clinical research study is to evaluate the safety of PEG-BCT- 100 given as an infusion to treat patients who bear advanced solid tumors that are dependent on arginine (melanoma, renal cell carcinoma, prostate cancer and hepatocellular carcinoma), and who have progressed after receiving approved or established therapies. This is a Phase 1 study; PEG-BCT-100 is an enzyme that degrades arginine and is an investigational drug.

Learn More About This Cancer Study

 

Fresno cancer clinical trials – (jump to San Diego clinical trials)

Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) Clinical Trial

Title: Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).

Learn More About This Cancer Study

 

Advanced Solid Malignancies

Title: A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination With Durvalumab in Patients With Advanced Solid Malignancies

This is a Phase I, open-label, multicenter study of continuous oral dosing of AZD4635 administered as a single agent and then in combination with a PD-L1 antibody, durvalumab. The study design allows an escalation of dose with intensive safety monitoring to ensure the safety of the patients. The primary objective of the study is to determine the maximum tolerated dose of AZD4635 in combination with durvalumab.

Learn More About This Cancer Study

 

Advanced Solid Tumor Clinical Trial

Title: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion.

Learn More about This Cancer Study

 

Advanced Solid Tumors Clinical Trial

Title: Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)

This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive MK-4280 as monotherapy or MK-4280 in combination with pembrolizumab. Part B is a dose confirmation design to estimate the recommended Phase 2 dose (RPTD) for MK-4280 in combination with pembrolizumab in participants with advanced solid tumors.

Learn More About This Cancer Study

 

Endocrine Therapy Clinical Trials

Title: Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.

Learn More About This Cancer Study

 

HER2 Negative, HR Positive, MBC (Contessa) Clinical Trial

Title: Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA) (CONTESSA)
The primary objective is to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive LA/MBC previously treated with a taxane in the neoadjuvant or adjuvant setting.

Approximately 600 eligible patients will be randomly assigned in a 1:1 ratio to either Arm A (tesetaxel plus a reduced dose of capecitabine) or Arm B (approved dose of capecitabine alone).

Learn More About This Cancer Study

 

Radiotherapy Clinical Trial

Title: Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy

MSC2490484A or M3814 is an investigational drug that is being evaluated for the treatment of subjects with locally advanced tumors. The main purposes of this study are to determine the safety, the tolerability and the efficacy of MSC2490484A in combination with radiotherapy and in combination with chemoradiotherapy (Radiotherapy + cisplatin).

Learn More About This Cancer Study